Please login to the form below

Not currently logged in
Email:
Password:

T-Vec

This page shows the latest T-Vec news and features for those working in and with pharma, biotech and healthcare.

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic

Latest news

  • Amgen gets FDA nod for virus-based melanoma therapy Amgen gets FDA nod for virus-based melanoma therapy

    Imlygic (talimogene laherparepvec or T-Vec) is a genetically modified live Herpes simplex virus that is designed to infect and destroy melanoma lesions in the skin and lymph nodes that cannot

  • Amgen’s immuno-oncology drug scores in skin cancer Amgen’s immuno-oncology drug scores in skin cancer

    Talimogene Laherparepvec (or T-Vec), which works as an investigational oncolytic immunotherapy, was compared to those who received granulocyte-macrophage colony-stimulating factor (GM-CSF). ... Amgen is already conducting trials of T-Vec alongside

  • FDA panel backs Amgen's T-Vec for melanoma FDA panel backs Amgen's T-Vec for melanoma

    FDA panel backs Amgen's T-Vec for melanoma. Approved by a panel of 22 to one despite questions on its impact on survival. ... Amgen is already conducting trials of T-Vec alongside Merck's Keytruda (pembrolizumab).

  • Amgen banking on three launches in 2015 Amgen banking on three launches in 2015

    year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for

  • ASCO: Amgen says viral therapy for melanoma ASCO: Amgen says viral therapy for melanoma "encouraging"

    ASCO: Amgen says viral therapy for melanoma "encouraging". T-VEC is potential advancement in skin cancer treatment. ... Amgen said it is carrying out early-stage combination studies with T-VEC.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics